Oral mucositis (OM) doesn't wax and wane like psoriasis does. I don't expect placebo effect to have much play in the Brilacidin ph2 OM trial.
I do agree with the concept of tempering ones' expectations in biotech investing. One never really knows what will show up in trial results. But, I'm expecting this trial to come up with good results.
In Reply to 'BioHedge'
If we see the same results as the interim, it would be an absolute moon shot result. And in my opinion, there is almost no way the numbers hold, to those levels, in a larger data set. I've always learned to temper my expectations in life and even more so in bio-tech investing. But, the great thing with B-OM is that there is no current effective treatment (bad for patients good for IPIX's new offering).
Overcoming the placebo effect is hard (look at the silence around Prurisol - had the numbers been coming in crazy good, we'd have heard rumblings). Take Otezla, there was a lot of board chatter that talked about how narrowly Otezla beat the placebo (like 10-15% or so if I remember correctly) but look at the revenues it's generated. I think the same can happen for B-OM.
We don't need to hit a grand-slam for this to be worth significant $$$. We just need it to work in a statistically meaningful way. As long as we get a decent spread from the placebo arm, we're golden.
Market Data 
Markets 
AI
